BridgeBio's Infigratinib Data Show First Statistically Significant Body Proportionality Improvement in Achondroplasia
Event summary
- BridgeBio's Phase 3 PROPEL 3 trial demonstrated a statistically significant improvement in annualized height velocity (AHV) with infigratinib, showing a mean treatment difference of +2.10 cm/year against placebo (p<0.0001).
- The trial also achieved the first statistically significant improvement in body proportionality in children under 8 years old (LS mean treatment difference of -0.05, p<0.05) – a key secondary endpoint.
- BridgeBio plans to submit an NDA and MAA in the second half of 2026 and will accelerate development for hypochondroplasia.
- Infigratinib was well-tolerated, with no discontinuations or serious adverse events related to the drug, and only a 4% incidence of mild, transient hyperphosphatemia.
The big picture
BridgeBio's success with infigratinib represents a significant advancement in treating achondroplasia, a rare genetic disorder with a substantial unmet need. The demonstration of improved body proportionality, beyond just height, positions infigratinib as a potentially transformative therapy. This achievement underscores the growing focus on addressing the broader health and functional impacts of rare diseases, rather than solely focusing on symptomatic relief.
What we're watching
- Regulatory Approval
- The FDA and EMA review timelines will be critical; a fast-track approval could significantly boost BridgeBio's valuation, while delays could raise concerns about efficacy or safety.
- Market Adoption
- The uptake of an oral therapy versus existing injectable treatments will depend on physician and patient preferences, and BridgeBio's ability to effectively communicate the body proportionality benefit.
- Expansion Potential
- The success of the hypochondroplasia development program will hinge on whether infigratinib's FGFR3-targeting mechanism proves effective in this related, but distinct, skeletal dysplasia.
Related topics